A recent foreign clinical trial showed albumin-bound paclitaxel(260mg/m2 tri-weekly)to have a better response for metastatic breast cancer(MBC)than did treatment with paclitaxel alone(175mg/m2 tri-weekly). It was sometimes difficult to control the occurrence of side effects, such as neutropenia and neuropathy, especially after many treatments. The effect of low-dose albumin-bound paclitaxel(180-220mg/m2 tri-weekly)was evaluated in 8 patients with MBC. The overall response rate was 62. 5%(CR 1, PR 4), and 2 cases had Grade 3/4 toxicity(Grade 3 neutropenia); however, all patients were manageable. In addition, there was a good response rate(50%, PR 3)among the patients previously treated with paclitaxel. Because patient's "care" is as important as the "cure" in the treatment of MBC, an effective and well-tolerated regimen is recommended for patients with this disease. Low-dose albumin-bound paclitaxel was effective with reduced side effects, even after PTX treatment. Therefore, albumin-bound paclitaxel may be an optional treatment for MBC after any treatment.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Low-dose apatinib in combination with chemotherapy for hormone receptor-positive, HER2-negative breast cancer with pulmonary lymphangitic carcinomatosis: A case report.
Medicine (Baltimore)
November 2024
Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, Guangdong, China.
Article Synopsis
- - A 48-year-old woman with hormone receptor-positive, HER2-negative advanced breast cancer developed pulmonary lymphangitic carcinomatosis (PLC) after ineffective treatment for a persistent cough.
- - She was treated with a combination of low-dose apatinib, capecitabine, and albumin-bound paclitaxel, which led to a partial response and improved symptoms over ten months.
- - This case suggests that apatinib may be a promising treatment for breast cancer patients with PLC, highlighting the need for tailored therapies and further research in this area.
Efficacy of vitamin C on chemotherapy-related anemia in pancreatic cancer: study protocol for a randomized controlled trial.
Trials
July 2024
Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Xuhui District, No. 270, Dong'An Road, Shanghai, 200032, China.
Background: In the treatment of advanced pancreatic cancer, chemotherapy plays a pivotal role. Despite its effectiveness, this regimen is often marred by side effects such as anemia, neuropathy, fatigue, nausea, and malnutrition, which significantly affect patients' tolerance to the treatment. Some studies have shown that vitamin C could potentially augment chemotherapy's tolerability, notably by boosting iron absorption, ameliorating anemia, and relieving pain and numbness in hands and feet.
View Article and Find Full Text PDFCase report: Immunotherapy-based combination therapy achieving complete remission and prolonged survival in nasopharyngeal carcinoma with extensive bone marrow metastasis.
Front Immunol
July 2024
Department of Oncology, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Article Synopsis
- Nasopharyngeal carcinoma with bone marrow metastasis has a very poor prognosis, making treatment challenging and necessitating personalized strategies.* -
- A case study of a 64-year-old man with recurrent nasopharyngeal carcinoma showed that an immunotherapy combination of pembrolizumab and low-dose cisplatin led to an initial positive response.* -
- The patient eventually achieved complete remission after transitioning to standard chemotherapy combined with pembrolizumab, demonstrating the effectiveness of tailored treatment in serious cases.*
Magnetic-optical dual-modality imaging monitoring chemotherapy efficacy of pancreatic ductal adenocarcinoma with a low-dose fibronectin-targeting Gd-based contrast agent.
Eur J Nucl Med Mol Imaging
June 2024
Department of Radiology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, No. 1 Shuaifuyuan, Beijing, 100730, China.
Purpose: Pancreatic ductal adenocarcinoma (PDAC) is a lethal hypovascular tumor surrounded by dense fibrosis. Albumin-bound paclitaxel and gemcitabine (AG) chemotherapy is the mainstay of PDAC treatment through depleting peritumoral fibrosis and killing tumor cells; however, it remains challenging due to the lack of a noninvasive imaging method evaluating fibrotic changes during AG chemotherapy. In this study, we developed a dual-modality imaging platform that enables noninvasive, dynamic, and quantitative assessment of chemotherapy-induced fibrotic changes through near-infrared fluorescence molecular imaging (FMI) and magnetic resonance imaging (MRI) using an extradomain B fibronectin (EDB-FN)-targeted imaging probe (ZD2-Gd-DOTA-Cy7).
View Article and Find Full Text PDFStandard versus low-dose nab-paclitaxel in previously treated patients with advanced non-small cell lung cancer: A randomized phase II trial (JMTO LC14-01).
Cancer Med
April 2023
Operations Office, The Japan-Multinational Trial Organization, Nagoya, Japan.
Background: Nab-paclitaxel (nab-PTX) has better transfer to tumor tissue than cremophor-based paclitaxel. It suggests that the optimum dose of nab-PTX might be lower than the dose and schedule that is widely used. We designed a randomized phase II trial to examine the clinical utility and safety of nab-PTX in patients with previously treated advanced non-small cell lung cancer (NSCLC).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!